Nivolumab recommended as a second-line treatment option for patients with two types of non-small-cell lung cancer

NICE draft guidance means patients with advanced squamous or non-squamous NSCLC will now be eligible for the second-line treatment on the NHS.

Please sign in or register for FREE

No comments yet.